Related Experiment Video

Updated: Feb 20, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.9K

CATNON conclusion: Closure on Concurrent Chemotherapy in IDHmt Grade 3 Astrocytoma

David Schiff1

  • 1Division of Neuro-Oncology, University of Virginia School of Medicine.

Neuro-Oncology
|February 18, 2026
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

1.2K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.4K

Related Experiment Videos

Last Updated: Feb 20, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.9K
A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

1.2K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.4K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K

Articles linked to this work by shared authors, journal, and citation graph.

Therapeutic delivery of microRNAs discovered to target deregulated glioblastoma pathways inhibits tumor growth in mice.

The Journal of clinical investigation·2026

Microenvironment T-Type calcium channels regulate neuronal and glial processes in tumor cells to promote glioblastoma growth.

Neuro-oncology·2026

Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801).

AJNR. American journal of neuroradiology·2026

Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Practical Management of Headaches in Patients With Primary and Secondary Brain Tumors.

Journal of pain and symptom management·2026

Identification of prognostically relevant residual tumor in glioblastoma after surgery: A comparative analysis of MR-based RANO resect classes vs. [18F]FET PET.

Neuro-oncology·2026

EGFR-co-amplified lncRNA ELDR drives glioblastoma tumorigenicity by enhancing BMI1 activity.

Neuro-oncology·2026

Conventionally Fractionated Re-irradiation for Recurrent Ependymoma.

Neuro-oncology·2026

Cell-Free DNA Sequencing Captures Tumor Dynamics, Microenvironment Interactions, and Treatment Pressures in Glioblastoma.

Neuro-oncology·2026

Cancer-intrinsic SIRPα Signaling Triggers Mitochondrial Fission and Immune Tolerance to Promote TNBC Breast-to-Brain Metastasis.

Neuro-oncology·2026

A CAR-T Tonic Signaling Code Predicts Anti-Tumor Efficacy in Diffuse Midline Glioma.

Neuro-oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us